Two non-invasive neuromodulation technologies — transcutaneous vagus nerve stimulation (tVNS) and transcutaneous spinal cord stimulation (tSCS) — are reshaping how we think about neurological rehabilitation.

Although they target different levels of the nervous system, these modalities share a surprising number of fundamental principles. Understanding these parallels gives clinicians, patients, and carers a clearer picture of how modern neuromodulation works, what to expect from treatment, and why these technologies represent a genuine shift from compensatory to restorative rehabilitation.

This article identifies ten fundamental parallels between tVNS and tSCS, drawing on the published scientific evidence to explore what they have in common, where they differ, and what this means for clinical practice.

This article focuses partly on a specific device: the tVNS® system, manufactured by tVNS Technologies GmbH in Germany. This is not a wellness gadget or an unregulated consumer product. The tVNS device is approved as a Class IIa medical device under the EU Medical Device Regulation (EU-MDR) with CE marking—currently the only non-invasive VNS device with this level of EU-MDR approval. It is registered for four specific clinical indications: epilepsy, depression, chronic migraines, and Prader-Willi syndrome. Anatomical Concepts (UK) is delighted to distribute and support the tVNS® system in the UK.

Why does this matter for rehabilitation? Because the same mechanisms that make vagus nerve stimulation effective for these approved conditions—neuroplasticity enhancement and anti-inflammatory action—are precisely the mechanisms that show promise for neurological rehabilitation. The ongoing research into stroke recovery, spinal cord injury, multiple sclerosis, and other conditions builds on a foundation of established science and regulatory-grade engineering.